The cytotoxicity of complex 1 was prominent and the fact that complex 1 downregulates the CD133 expression in cancer cells along with the strong reduction of the SCF secretion in two aggressive tumor cell lines suggests a potential applicability as prodrug. This evidence concerns the gene PROM1 and cancer.